APPLICATION OF GENOTYPING CYP3A5 POLYMORPHISM FOR CORRECTING DOSE OF TACROLIMUS IN KIDNEY TRANSPLANTATION

Cover Page


Cite item

Full Text

Abstract

Currently, according to standard immunosuppression protocols after organ transplantation, tacrolimus is used as a part of immunosuppressive therapy. Along with obtaining the desired immunosuppressive effect, the problem of the development of unwanted adverse reactions to this drug is highly relevant. Pharmacogenetic testing of genotyping of the polymorphism of CYP3A5 G6986A, allows a personalized approach to the selection of the dosing regimen of tacrolimus, may increase the number of patients in whom the concentration of tacrolimus will be within the therapeutic range and will not exceed the acceptable toxicity level.

About the authors

M. R. Ruzibakiyeva

Institute of Human Immunology and Genomics, Academy of Sciences of Uzbekistan

Author for correspondence.
Email: malika-ruz@hotmail.com

PhD, Senior Researcher,

Tashkent

Uzbekistan

T. U. Aripova

Institute of Human Immunology and Genomics, Academy of Sciences of Uzbekistan

Email: fake@neicon.ru

MD, Academician of the Academy of Sciences of Uzbekistan, Director of the Institute,

Tashkent

Uzbekistan

F. A. Hadzhibaev

Republican Specialized Scientific Center for Emergency Medical Aid of the Ministry of Health of the Republic of Uzbekistan

Email: fake@neicon.ru

D.M.S., Head of Surgery Department,

Tashkent

Uzbekistan

V. Kh. Sharipov

Republican Specialized Scientific Center for Emergency Medical Aid of the Ministry of Health of the Republic of Uzbekistan

Email: fake@neicon.ru

MD, Head of the Department of Anaesthesiology and Reanematology,

Tashkent

Uzbekistan

Z. Sh. Azizova

Institute of Human Immunology and Genomics, Academy of Sciences of Uzbekistan

Email: fake@neicon.ru

junior researcher,

Tashkent

Uzbekistan

References

  1. Середенин С. Б. Лекции по фармакогенетике // М.: МИА, 2004. –303 с.
  2. Сычев Д. А., Игнатьев И. В., Раменская Г. В., Кукес В. Г. Клиническая фармакогенетика / Под ред. В. Г. Кукеса, Н. П. Бочкова. – М.: ГЭОТАРМЕДИА, 2007. – 248 с.
  3. Diasio R. B., Beavers T. L., Carpenter J. T. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity // J. Clin. Invest. – 1988. – Vol. 81. – P. 47–51.
  4. Lemoine A., Daniel A., Dennison A., Kiffel L., Lydiane P., Valérie F., Thierry B., Gilles F., Brigitte D., Patrick M., Henri B., Philippe B. FK 506 renal toxicity and lack of detectable cytochrome P-450 3A in the liver graft of a patient undergoing liver transplantation // Hepatology. – 1994. – Vol. 20. – P. 1472–1477.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Ruzibakiyeva M.R., Aripova T.U., Hadzhibaev F.A., Sharipov V.K., Azizova Z.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies